Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E5VP
|
|||
| Former ID |
DIB006234
|
|||
| Drug Name |
KF-66490
|
|||
| Synonyms |
K-34; PDE 4 inhibitors (dermatitis/rheumatoid arthritis); PDE 4 inhibitors (dermatitis/rheumatoid arthritis), Kyowa Hakko Kirin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Investigative | [1] | |
| Company |
Kyowa Hakko Kirin Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N4O5
|
|||
| Canonical SMILES |
CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N5CC5)OC)N4C)N
|
|||
| InChI |
1S/C18H22N4O5/c1-8-12(19)15(24)11-9(7-27-17(25)21-4-5-21)18(26-3)16-10(20(16)2)6-22(18)13(11)14(8)23/h9-10,16H,4-7,19H2,1-3H3
|
|||
| InChIKey |
FZLZUGFFXNJCRD-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [1] |
| Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [1] | |
| Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Purine metabolism | |||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | DARPP-32 events | |||
| G alpha (s) signalling events | ||||
| WikiPathways | G Protein Signaling Pathways | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Opioid Signalling | ||||
| TSH signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol. 2009 Jan;9(1):55-62. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.